This Article Abstract Full Text (PDF) Data Supplement All Versions of this Article: 25/12/2567    most recent 01.ATV.0000190672.36490.7bv1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Damås, J. K. Articles by Quehenberger, O. Search for Related Content PubMed PubMed Citation Articles by Damås, J. K. Articles by Quehenberger, O.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:2567.)
© 2005 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Expression of Fractalkine (CX3CL1) and its Receptor, CX3CR1, Is Elevated in Coronary Artery Disease and Is Reduced During Statin Therapy

Jan K. Damås; Agnes Boullier; Torgun Wæhre; Camilla Smith; Wiggo J. Sandberg; Simone Green; Pål Aukrust; Oswald Quehenberger

From the Department of Medicine (J.K.D., A.B., S.G., O.Q.), University of California, San Diego, La Jolla; and the Research Institute for Internal Medicine (J.K.D., T.W., C.S., W.J.S., P.A.), the Department of Cardiology (T.W.), and the Section of Clinical Immunology and Infectious Diseases (P.A.), Rikshospitalet, University of Oslo, Norway.

Correspondence to Jan K. Damås, Research Institute for Internal Medicine, Rikshospitalet, N-0027 Oslo, Norway. E-mail j.k.damas{at}klinmed.uio.no; or Oswald Quehenberger, University of California, San Diego, Department of Medicine, La Jolla, CA 92093. E-mail oquehenberger@ucsd.edu

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Objective— Recent data derived primarily from studies in animal models suggest that fractalkine (CX3CL1) and its cognate receptor, CX3CR1, play a role in atherogenesis. We, therefore, hypothesized that enhanced CX3CL1/CX3CR1 expression may promote atherogenesis in patients with coronary artery disease (CAD).

Methods and Results— We examined the plasma levels of CX3CL1 and CX3CR1 expression in peripheral blood mononuclear cells (PBMC) in various CAD populations (30 patients with previous myocardial infarction, 40 patients with stable angina, 40 patients with unstable angina, and a total of 35 controls) and used various experimental approaches to characterize CX3CL1-mediated leukocyte responses. We found that the plasma levels of CX3CL1 are greatly increased in CAD, particularly in unstable disease. The parallel increase of CX3CR1 expression in PBMC was predominantly attributable to an expansion of the CX3CR1⁺CD3⁺CD8⁺ T cell subset and was associated with enhanced chemotactic, adhesive, and inflammatory responses to CX3CL1. Statin therapy for 6 months reduced the expression of CX3CL1 and CX3CR1, reaching statistical significance for both parameters only during aggressive (atorvastatin, 80 mg qd) but not conventional (simvastatin, 20 mg qd) therapy. Consequently, the functional responses of the PBMC to CX3CL1 including migration, adhesion, and secretion of interleukin-8 were attenuated by the treatments.

Conclusion— Our results suggest that the CX3CL1/CX3CR1 dyad may contribute to atherogenesis and plaque destabilization in human CAD.

We show increased plasma levels of CX3CL1 and enhanced expression of its cognate receptor, CX3CR1, on T cells in patients with coronary artery disease. These changes were accompanied by an increased chemotactic and adhesive response to CX3CL1. Statin therapy reduced the CX3CL1/CX3CR1 levels and normalized the functional responses to CX3CL1.

Key Words: atherosclerosis • coronary artery disease • cytokines • immune system • leukocytes

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Besides lipid deposition and vascular smooth muscle cell (VSMC) proliferation, the infiltration of monocytes and T cells is a cardinal feature of atherosclerotic plaques of all stages.^1,2 This persistent recruitment of mononuclear cells into the vessel wall is a critical step in atherogenesis, and growing evidence suggests that chemokines are involved in these processes by activating and directing leukocytes into atherosclerotic lesions.^3,4

Fractalkine (CX3CL1) is the unique member of the CX3C chemokine subfamily. In contrast to other chemokines, it exists in two forms, each mediating distinct biological actions.⁵ The membrane-anchored protein, which is expressed primarily on the inflamed endothelium, serves as an adhesion protein promoting the retention of monocytes and T cells.⁶ The soluble form resembles more a conventional chemokine and strongly induces chemotaxis. Both chemotaxis and adhesion are mediated by the G protein–coupled receptor CX3CR1.^7,8 Based on these chemotactic and adhesive properties, CX3CL1 has been suggested to play an important role in inflammation and accumulating evidence indicates that CX3CL1/CX3CR1 are involved in the pathogenesis of various inflammatory disorders.^9,10

Recently, two independent reports showed that the targeted deletion of CX3CR1 decreased atherosclerosis in mice, implicating a role of this chemokine system in atherogenesis.^11,12 Moreover, Lucas et al and Greaves et al have recently shown expression of CX3CL1 and CX3CR1 in human coronary atherosclerotic plaques,^13,14 and polymorphisms in the CX3CR1 gene have been shown to be associated with coronary events.^15–17 However, the role of the CX3CL1/CX3CR1 dyad in human coronary artery disease (CAD), and particularly in unstable disease, remains unclear. The present study was designed to further elucidate the potential role of CX3CL1/CX3CR1 in human CAD by examining the expression of CX3CL1 and its receptor in CAD patients, including patients with stable and unstable angina. We also investigated the ability of 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) reductase inhibitors (statins) to modulate CX3CL1/CX3CR1 levels in these patients.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Patients and Controls
In the angina study we included 40 patients with unstable angina (defined as ischemic chest pain at rest within the preceding 48 hours, transient ST-T-segment depression, and/or T-wave inversion but with no evidence of myocardial necrosis by enzymatic criteria) and 40 patients with stable angina (defined as effort angina >3 months and a positive exercise test) (Table I, available online at http://atvb.ahajournals.org). The diagnosis of CAD was confirmed by coronary angiography. For the statin study, we had available to us human plasma and leukocytes obtained for an unrelated study described previously.¹⁸ Briefly, 30 patients with previous myocardial infarction without prior statin treatment were included and randomized to simvastatin 20 mg qd (n=15) or atorvastatin 80 mg qd (n=15) therapy for 6 months in an open study (Table II, available online at http://atvb.ahajournals.org), representing both conventional and aggressive statin therapy, respectively. Exclusion criteria in both studies were myocardial infarction or thrombolytic treatment within the previous 6 weeks, severe concomitant disease (eg, infections, connective tissue disease, or malignancies), congestive heart failure, and the use of medications other than aspirin with known antiinflammatory effects. For comparison, blood was collected from 35 healthy controls (20 in the angina study and 15 in the statin study) matched for age, sex, and smoking habits (Tables I and II). The controls were health care workers, consecutively recruited from the same area of Norway as the patients (eastern part). Although asymptomatic CAD cannot be totally excluded, all the controls were evaluated as healthy based on clinical examination, disease history, and analyses of C-reactive protein (CRP) and lipid parameters. The regional ethical committee approved all parts of the study, and all individuals gave their informed consent.

Isolation of Cells and Plasma
Peripheral blood mononuclear cells (PBMC) were obtained from heparinized blood by Isopaque–Ficoll gradient centrifugation, and separation of monocytes and CD3⁺ T cells from freshly isolated PBMC was performed as described elsewhere.^19,20 For details, please see the expanded Methods, available online at http://atvb.ahajournals.org.

Cell Culture
Thawed cryopreserved PBMC and primary human umbilical vein endothelial cells (HUVEC) were cultured as described previously (please see the expanded online Methods).²¹

Chemotaxis and Adhesion Assays
CX3CL1-mediated chemotactic activities and adhesion were examined with thawed cryopreserved PBMC or freshly isolated T cells and monocytes (please see the expanded online Methods).

Real-Time Quantitative Reverse Transcriptase–Polymerase Chain Reaction
mRNA levels of CX3CL1 and CX3CR1 were quantified by real-time quantitative RT-PCR (please see the expanded online Methods).

Flow Cytometry
Flow cytometry analyses of thawed cryopreserved PBMC were performed using a FACSCalibur instrument with CellQuest software (Becton Dickinson Bioscience) (please see the expanded online Methods).

Miscellaneous
Protein levels of CX3CL1, interleukin (IL)-8, monocyte chemoattractant peptide (MCP)-1, macrophage inflammatory protein (MIP)-1, and soluble (s) CD25 were determined by enzyme immunoassays (EIA; R&D Systems). Levels of CRP were measured by EIA obtained from DAKO. The endotoxin levels in all culture media, buffers, and stimulants were <10 pg/mL (Limulus Amebocyte Lysate Assay).

Statistical Analysis
For comparison of 2 groups, the Mann–Whitney U test was used. When more than 2 groups of individuals were compared (as in Figure 1), the nonparametric Kruskal–Wallis test was used. If a significant difference was found, Mann–Whitney U test was used to calculate the difference between each pair of groups. For comparison within the same individuals, the Wilcoxon matched-pairs test was used. Coefficients of correlation were calculated by the Spearman rank test. Data are given as mean±SEM unless otherwise stated. Probability values are 2-sided and considered significant when <0.05.

View larger version (14K): [in this window] [in a new window]   Figure 1. A, Plasma levels of CX3CL1 in 40 patients with stable and 40 patients with unstable angina pectoris (AP) and 20 healthy controls. B, mRNA levels of CX3CR1 in PBMC from 20 stable and 20 unstable AP patients (randomly selected from the angina population) and 20 healthy controls. The mRNA levels were quantified using real-time RT-PCR and data were normalized to ß-actin gene expression. Horizontal lines represent the median values.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Expression of CX3CL1 and CX3CR1 in Angina Patients
As shown in Figure 1, both stable (756±72 pg/mL) and unstable (1199±112 pg/mL) angina patients had significantly increased plasma levels of CX3CL1, compared with healthy controls (423±25 pg/mL). The increase was highly significant and was particularly pronounced in unstable disease (P<0.001 versus stable angina). Analyses of PBMC transcripts showed that CX3CR1 expression was also substantially higher in the angina patients and, like CX3CL1, was particularly elevated in patients with unstable disease (P<0.01 versus stable angina; Figure 1). In fact, 32 of the 40 patients with unstable angina had higher plasma levels of CX3CL1 than the highest concentration in healthy controls, and as for CX3CR1 expression there was no overlap between unstable angina patients and controls. The unstable patients with the highest CX3CL1 levels (>median) were not significantly different from the other individuals in this group with regard to sex, smoking habits, diabetes, or plasma cholesterol levels. Moreover, there was no correlation between CRP levels and either CX3CL1 or CX3CR1 expression within the angina patients (data not shown).

Reduction of CX3CL1 and CX3CR1 Expression by Statin Therapy
To examine the effect of statin treatment on CX3CL1 and CX3CR1 levels, a group of 30 CAD patients was examined before and after therapy. Before the start of the statin therapy, the patients exhibited significantly elevated plasma levels of CX3CL1 (P<0.01) and enhanced PBMC expression of CX3CR1 (P<0.001) compared with controls (Figure 2). More detailed analysis by flow cytometry showed that although the CX3CR1 expression on monocytes was similar between patients and controls, the fraction of CX3CR1-expressing CD3⁺ T cells was significantly increased in the CAD group (P<0.001), which was mainly attributable to an expansion of the CX3CR1-expressing CD3⁺CD8⁺ T cell subset (Figure 2; Figure I, available online at http://atvb.ahajournals.org). Compared with controls, the CD3⁺ T cells from CAD patients showed a 3.2-fold increase in CX3CR1 expression, the corresponding increase on CD8⁺CD3⁺ T cells was 1.7-fold, and no change was observed with CD4⁺CD3⁺ T cells.

View larger version (22K): [in this window] [in a new window]   Figure 2. Plasma levels of CX3CL1 (A), mRNA levels of CX3CR1 in PBMC (B), and protein expression of CX3CR1 on CD14+ monocytes (C), CD3+ T cells (D), CD4+ T cells (E), and CD8+T cells (F) in 30 patients with coronary artery disease (CAD) and 15 healthy controls (from the statin study). CX3CR1 surface expression was measured by flow cytometry, and data are presented as the percentage of the total amount of CD14+, CD3+, CD4+, and CD8+ cells, respectively. Horizontal lines represent the median values.

As expected, treatment of CAD patients with statins for 6 months reduced their plasma levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides (Table II). In addition, atorvastatin (from 794±151 to 587±89, P<0.05, n=15) but not simvastatin (from 1141±165 to 1051±183, n.s., n=15) significantly lowered the plasma levels of CX3CL1 (Figure 3). The lowering was still significant when the data from both treatment groups were combined (from 968±114 pg/mL to 819±109 pg/mL, P<0.05, n=30). Moreover, both simvastatin and atorvastatin reduced the mRNA levels of CX3CR1 in PBMC (from 4.6±0.6 to 3.4±0.5, CX3CR1:ß-actin mRNA ratio, P<0.001; both treatment groups were combined, n=30; Figure 3). However, although the statin treatment did not affect CX3CR1 expression on monocytes (data not shown), atorvastatin and to a lesser extent simvastatin reduced the fraction of CX3CR1-expressing CD3⁺CD8⁺ T cells (71.7±2.5% versus 55.5±3.0%, P<0.01, both groups were combined, n=14; Figure 3 and Figure I).

View larger version (28K): [in this window] [in a new window]   Figure 3. Plasma levels of CX3CL1 (A and B), mRNA levels of CX3CR1 in PBMC (C and D), and protein expression of CX3CR1 on CD8+ T cells (E and F) in CAD patients at baseline and after 6 months (mo) of simvastatin (20 mg qd, n=15) or atorvastatin (80 mg qd, n=15) therapy. G, Correlation between mRNA levels of CX3CR1 and LDL cholesterol levels at baseline. The mRNA levels were quantified using real-time RT-PCR, and data were normalized to ß-actin gene expression. CX3CR1 surface expression was measured using flow cytometry, and data are presented as the percentage of the total amount of CD8+ cells. There were no significant differences in changes between the atorvastatin and simvastatin treatment groups for any of the parameters. Dotted line represents mean values in healthy controls. Mean values±SEM at baseline and after 6 months are illustrated in A through F.

Correlations Between LDL Cholesterol and CX3CL1/CX3CR1 Expression
Analysis of the lipid parameters and CX3CL1/CX3CR1 levels indicated a significant correlation between CX3CR1 expression in circulating PBMC and LDL cholesterol levels in CAD patients at baseline (r=0.44, P<0.05; Figure 3). In addition, the decrease in CX3CR1 mRNA was also significantly correlated with the decrease in LDL cholesterol during statin therapy (r=0.51, P<0.05; both groups were combined, n=30). Such correlations with LDL levels at baseline were also seen when CX3CR1 expression was assessed on CD3⁺ T cells by flow cytometry (r=0.56, P<0.05), although the correlations did not reach statistical significance for changes in these parameters during statin therapy. In contrast, no significant correlation was found between plasma levels of CX3CL1 and LDL cholesterol either at baseline or during statin treatment.

Inhibition of Endothelial CX3CL1 Release by Statins
To further examine whether the statins exert the CX3CL1/CX3CR1 related effects at the cellular or at a systemic level through lowering plasma concentrations of cholesterol, we tested the ability of atorvastatin to modulate the release and gene expression of CX3CL1 in HUVEC. To mimic the in vivo situation in CAD, the cells were stimulated for 20 hours with IL-1ß, an inflammatory cytokine known to be upregulated in CAD.¹⁸ Atorvastatin potently reduced the IL-1ß–stimulated gene expression and release of CX3CL1 in HUVEC (Figure II, available online at http://atvb.ahajournals.org). This inhibition was reversed by the addition of mevalonate, suggesting that this effect of statin may be operative at the cellular level. In contrast, neither atorvastatin nor mevalonate had any effect on the IL-1ß–stimulated expression of CX3CR1 in PBMC from healthy controls (n=5) under identical experimental conditions (data not shown).

CX3CR1-Mediated Chemotaxis and Adhesion
To elucidate the functional implications of enhanced CX3CR1 expression, we next examined the chemotactic and adhesive properties of PBMC from CAD patients and healthy controls. CX3CL1 induced chemotaxis in a dose-dependent manner in cells from both CAD patients and controls; however, the response was higher in PBMC from CAD patients (Figure 4). Although the number of migrated cells in the CAD group at baseline appears somewhat dispersed, there was no correlation between the chemotactic activity and plasma levels of CX3CL1 within the group. Statin therapy attenuated the chemotactic response to levels characteristic for cells from healthy controls (Figure 4). Cell adhesion was also higher with the PBMC from the CAD patients. Again, statin therapy significantly decreased the adhesive property to CX3CL1; however, the effect was more modest compared with chemotaxis (Figure 4). The extent of the reductions was similar for both atorvastatin and simvastatin and the data were, therefore, combined.

View larger version (24K): [in this window] [in a new window]   Figure 4. Chemotaxis in response to various concentrations of soluble CX3CL1 (A) and adhesion in response to immobilized CX3CL1 (B) of cryopreserved PBMC collected from healthy controls (n=8) and CAD patients (n=16) before and after 6 months (mo) of statin therapy (simvastatin, 20 mg qd, n=8 and atorvastatin, 80 mg qd, n=8). Both drugs had similar effect on chemotaxis and adhesion and the results were combined. The number of migrated and adherent cells was determined by counting the cells in five random high power (x400) fields and expressed as the mean number of cells per field. Shown is the specific migration after subtraction from the total the nonspecific migration determined in the absence of CX3CL1 (on average 4 to 6 cells). Data are mean±SEM. *P<0.05 and **P<0.01 vs healthy controls; # P<0.05 vs baseline.

To substantiate the results obtained with cryopreserved cells, we performed chemotaxis and adhesion assays using freshly purified CD14⁺ monocytes and CD3⁺ T cells from 7 CAD patients and 7 healthy controls. Compared with the cells from healthy controls, the freshly isolated CD3⁺ T cells from the CAD patients showed significantly increased adhesion to CX3CL1 (25.0±2.7 versus 9.6±1.6 cells per field, P<0.05) and migration (38.1±2.5 versus 15.2±2.2 cells per field, P<0.05; 10 nmol/L CX3CL1). In contrast, no such difference was found with freshly isolated CD14⁺ monocytes.

Effect of CX3CL1 on Chemokine Levels in PBMC Supernatants
Exposure of leukocytes to inflammatory conditions can trigger the secretion of cytokines that may lead to cell activation via paracrine or autocrine mechanisms. Because IL-8 is critically involved in atherogenesis and plaque destabilization,⁴ we examined the efficacy of CX3CL1 to stimulate the secretion of this chemokine. As shown in Figure III (available online at http://atvb.ahajournals.org), the IL-8 secretion was significantly higher in PBMC from CAD patients compared with controls, and this elevated level was further increased by exogenous CX3CL1. Interestingly, although the CX3CL1 chemokine domain by itself was sufficient to induce chemotaxis (see above), it did not stimulate the expression of IL-8 (data not shown). For effective stimulation of IL-8 secretion, the full-length extracellular domain of CX3CL1 was required. The reason for this is not clear, but some cellular responses my entail specific modes of interaction with CX3CR1 that involve the mucine stalk of the chemokine.²² The effect of CX3CL1 on chemokine secretion seemed to be specific for IL-8, and no changes in the other chemokines including MCP-1 and MIP-1 were observed (data not shown). As with adhesion and chemotaxis, statin treatment markedly attenuated this CX3CL1-stimulated IL-8 release (Figure III). Atorvastatin and simvastatin were similar in their efficacy and the data were, therefore, combined.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
In the present study, we show that the plasma levels of CX3CL1 are greatly increased in CAD patients, particularly in those with unstable disease. Concomitantly, the CX3CR1-expressing leukocytes, primarily CD3⁺CD8⁺ T cells, were significantly expanded in these patients. Although continuous or repeated stimulation of G protein–coupled receptors by their agonists may reduce their responsiveness (eg, desensitization),²³ the changes in CX3CL1 plasma levels did not impair receptor function and the CX3CR1-expressing leukocytes displayed enhanced chemotactic, adhesive, and other inflammatory responses. Notably, statin therapy reduced the expression of CX3CL1 and CX3CR1 in CAD patients and attenuated the functional responses of the circulating leukocytes to CX3CL1, including chemotaxis and adhesion as well as inflammatory responses such as IL-8 secretion.

Although atherosclerosis was traditionally considered a simple lipid disorder, the inflammatory component of the diseases has gained appreciation in recent years. Consistent with this, increased expression of CX3CR1 and CX3CL1 has been reported in human atherosclerotic lesions.^13,14 Furthermore, results from recent genetic and functional studies suggested a significant association between CX3CR1 polymorphisms and risk of CAD.^15–17 The present study further supports an important role of the CX3CL1/CX3CR1 dyad in leukocyte infiltration and propagation of inflammatory responses within atherosclerotic lesions. In addition, the expression of several other chemokines and receptors is increased in CAD,²⁴ underscoring the inflammatory component of the disease and suggesting that a dysregulated chemokine network and specifically the CX3CL/CX3CR1 system are important factors in atherogenesis.

Within the leukocyte population, T cells appear to be particularly susceptible to undergo phenotypic changes under conditions of CAD and the fraction of CX3CR1-expressing T cells, specifically the CX3CR1⁺CD3⁺CD8⁺ T cells, were markedly increased in these patients. However, whereas CX3CR1 expression increased 3.2-fold on CD3⁺ T cells, the corresponding increase on CD3⁺CD8⁺ T cells was only 1.7-fold, suggesting that an additional subpopulation may contribute to CX3CR1 expression among the CD3⁺ T cell population. Potential candidates include CD3⁺CD4^–CD8^– T cells, but this issue will need to be further evaluated in forthcoming studies. Nevertheless, previous studies have shown that CX3CR1⁺ T cells are terminally differentiated effector phenotypes with enhanced cytotoxic properties.²⁵ Moreover, the excessive activation of cytotoxic T cells has been associated with incidental vascular and tissue damage.²⁶ Therefore, the disproportional increase in CX3CR1⁺CD3⁺CD8⁺ T cells in CAD may be of particular importance for disease initiation and progression. The ability of CX3CL1/CX3CR1 to enhance the effector function of CD8⁺ T cells²⁷ may further support a pathogenic role for CX3CR1-expressing CD8⁺ T cells in atherogenesis. Nevertheless, a recent study with human atherosclerotic tissues found no colocalization of CX3CR1 with CD3⁺ T cells.¹³ These findings are inconsistent with our results; however, the differences can be explained by the phenotypic changes T cells may undergo. The expression of CX3CR1 on CD3⁺ lymphocytes is negatively regulated by T cell activation,⁷ and the low expression of CX3CR1 on CD3⁺ T cells in lesions may reflect downregulation that occurred after cell recruitment in response to local activation signals. Consistent with an important role in the recruitment process and inflammation, CX3CR1 was found to be preferentially expressed in Th1 cells compared with Th2 cells and has been suggested to play an important role in Th1-dominated inflammatory disorders including atherosclerosis.²⁸

Experimental as well as some clinical data indicate that statins may confer cardiovascular benefits in addition to the lipid lowering activity.²⁹ These pleiotropic effects of statins function in part by modulating the inflammatory arm of atherosclerosis. In the present study, we show that besides lowering plasma lipid levels, statin treatment also attenuated the expression of CX3CR1 and CX3CL1 and reduced some of the excessive CX3CL1-mediated inflammatory responses in CAD patients. Although some of these responses appear to be more pronounced in the atorvastatin group, caution should be exercised when comparing the two statin groups because of the relatively low number of patients that were studied. The differences between the aggressive (atorvastatin 80 mg qd) and conventional (simvastatin 20 mg qd) treatment group are small and may be attributable to slight differences in the lipid-lowering capacity rather than class differences. Consistent with this, we found a significant correlation between the plasma levels of LDL cholesterol and CX3CR1 gene expression in PBMC, predominantly T cells, both before and during statin treatment. Furthermore, ex vivo treatment of PBMC with statin had no effect on CX3CR1 expression. The statin-mediated effect on T cells may not be specific for CX3CR1. For example, statins have been shown to suppress also interferon-–expressing T cells and to downregulate markers of T cell activation (eg, HLA-DR and CD38) in CAD.^30,31 In addition, we found that statin therapy significantly attenuated the release of sCD25 from PBMC, a widely used marker of T cell activation (data not shown). These results imply that the conditions of CAD cause a global stimulation of T cell programs and are suggestive of a more general systemic modulation of the inflammatory status of T cells by statins.

In contrast to CX3CR1, no statistical correlation was found between plasma levels of lipids and CX3CL1, and more importantly, treatment of cytokine-activated endothelial cells with statin markedly reduced the CX3CL1 secretion in vitro. Although we have no direct data addressing specifically the proteolytic cleavage of CX3CL1 from the cell surface, the observed decrease at both the mRNA and protein level suggests that their suppressive effect on the IL-1ß–mediated CX3CL1 release from endothelial cells does not merely reflect attenuated proteolytic cleavage of membrane-bound CX3CL1. These findings indicate that the property of the statins on CX3CL1 secretion may be independent of plasma lipid levels and may be operative at the cellular level. Similar antiinflammatory benefits of statins have also been reported in non-CAD patients (eg, multiple sclerosis),³² further supporting that the immunomodulatory effects of statins are not merely a secondary phenomenon to lipid lowering.

In the present study we have shown that the plasma levels of CX3CL1 and T cell expression of CX3CR1 are elevated in CAD patients. We have further shown that statin therapy attenuated the expression of these inflammatory mediators as well as the inflammatory response of the PBMC to CX3CL1. Our findings suggest that the CX3CL1/CX3CR1 chemokine system may constitute a therapeutic target in the care of CAD patients including those with unstable disease.

	Acknowledgments

 
This work was supported by the National Institutes of Health grant HL56989 (La Jolla Specialized Center of Research in Molecular Medicine and Atherosclerosis) and by the Norwegian Research Council and by Medinnova Foundation.

Received March 30, 2005; accepted September 28, 2005.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001; 104: 503–516.[CrossRef][Medline] [Order article via Infotrieve]
2. Hansson GK, Libby P, Schönbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002; 91: 281–291.[Abstract/Free Full Text]
3. Boring L, Gosling J, Cleary M, Cleary M, Charo IF. Decreased lesion formation in CCR2–/– mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998; 394: 894–897.[CrossRef][Medline] [Order article via Infotrieve]
4. Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor–deficient mice. J Clin Invest. 1998; 101: 353–363.[Medline] [Order article via Infotrieve]
5. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ. A class of membrane-bound chemokine with a CX3C motif. Nature. 1997; 385: 640–644.[CrossRef][Medline] [Order article via Infotrieve]
6. Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, Patel DD. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med. 1998; 188: 1413–1419.[Abstract/Free Full Text]
7. Imai T, Hieshima, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ, Yoshie O. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997; 91: 521–530.[CrossRef][Medline] [Order article via Infotrieve]
8. Combadiere C, Salzwedel K, Smith ED, Tiffany HL, Berger EA, Murphy PM. Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J Biol Chem. 1998; 273: 23799–23804.[Abstract/Free Full Text]
9. Chen S, Bacon KB, Li L, Garcia GE, Xia Y, Lo D, Thompson DA, Siani MA, Yamamoto T, Harrison JK, Feng L. In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II. J Exp Med. 1998; 188: 193–198.[Abstract/Free Full Text]
10. Ruth JH, Volin MV, Haines GK 3rd, Woodruff DC, Katschke KJ Jr, Woods JM, Park CC, Morel JC, Koch AE. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum. 2001; 44: 1568–1581.[CrossRef][Medline] [Order article via Infotrieve]
11. Combadiere C, Potteaux S, Gao JL, Esposito B, Casanova S, Lee EJ, Debre P, Tedgui A, Murphy PM, Mallat Z. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation. 2003; 107: 1009–1016.[Abstract/Free Full Text]
12. Lesnik P, Haskell CA, Charo IF. Deceased atherosclerosis in CX3CR1^–/– mice reveals a role for fractalkine in atherogenesis. J Clin Invest. 2003; 111: 333–340.[CrossRef][Medline] [Order article via Infotrieve]
13. Lucas AD, Bursill C, Guzik TJ, Sadowski J, Channon KM, Greaves DR. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation. 2003; 108: 2498–2504.[Abstract/Free Full Text]
14. Greaves DR, Hakkinen T, and Lucas AD. Liddiard K, Jones E, Quinn CM, Senaratne J, Green FR, Tyson K, Boyle J, Shanahan C, Weissberg PL, Gordon S, Yla-Hertualla S. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2001; 21: 923–929.[Abstract/Free Full Text]
15. Moatti D, Faure S, Fumeron F, Amara Mel-W, Seknadji P, McDermott DH, Debre P, Aumont MC, Murphy PM, de Prost D, Combadiere C. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood. 2001; 97: 1925–1928.[Abstract/Free Full Text]
16. McDermott DH, Halcox JP, Schenke WH, Waclawiw MA, Merrell MN, Epstein N, Quyyumi AA, Murphy PM. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular dysfunction and atherosclerosis. Circ Res. 2001; 89: 401–407.[Abstract/Free Full Text]
17. McDermott DH, Fong AM, Yang Q, Sechler JM, Cupples LA, Merrell MN, Wilson PW, D’Agostino RB, O’Donnell CJ, Patel DD, Murphy PM. Chemokine receptor mutant CX3CR1–M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest. 2003; 111: 1241–1250.[CrossRef][Medline] [Order article via Infotrieve]
18. Wæhre T, Yndestad A, Smith C, Haug T, Tunheim SH, Gullestad L, Frøland SS, Semb AG, Aukrust P, Damås JK. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation. 2004; 109: 1966–1972.[Abstract/Free Full Text]
19. Aukrust P, Aandahl EM, Skalhegg BS, Nordøy I, Hansson V, Tasken K, Frøland SS, Muller F. Increased activation of protein kinase A type I contributes to the T cell deficiency in common variable immunodeficiency. J Immunol. 1999; 162: 1178–1185.[Abstract/Free Full Text]
20. Stylianou E, Aukrust P, Muller F, Nordøy I, Frøland SS. Complex effects of interferon-alpha on the cytokine network in HIV infection–possible contribution to immunosuppression. Cytokine. 2001; 14: 56–62.[CrossRef][Medline] [Order article via Infotrieve]
21. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973; 52: 2745–2756.
22. Fong AM, Erickson HP, Zachariah JP, Poon S, Schamberg NJ, Imai T, Patel DD. Ultrastructure and function of the fractalkine mucin domain in CX(3)C chemokine domain presentation. J Biol Chem. 2000; 275: 3781–3786.[Abstract/Free Full Text]
23. Lefkowitz RJ, Whalen EJ. Beta-arrestins: traffic cops of cell signaling. Curr Opin Cell Biol. 2004; 16: 162–168.[CrossRef][Medline] [Order article via Infotrieve]
24. Wæhre T, Damås JK, Gullestad L, Holm AM, Pedersen TR, Arnesen KE, Torsvik H, Frøland SS, Semb AG, Aukrust P. Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol. 2003; 41: 1460–7146.[Abstract/Free Full Text]
25. Nishimura M, Umehara H, Nakayama T, Yoneda O, Hieshima K, Kakizaki M, Dohmae N, Yoshie O, Imai T. Dual function of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol. 2002; 168: 6173–6180.[Abstract/Free Full Text]
26. Umehara H, Bloom E, Okazaki T, Domae N, Imai T. Fractalkine and vascular injury. Trends Immunol. 2001; 22: 602–607.[CrossRef][Medline] [Order article via Infotrieve]
27. Combadiere B, Faure S, Autran B, Debre P, Combadiere C. The chemokine receptor CX3CR1 controls homing and anti-viral potencies of CD8 effector-memory T lymphocytes in HIV-infected patients. AIDS. 2003; 17: 1279–1290.[CrossRef][Medline] [Order article via Infotrieve]
28. Fraticelli P, Sironi M, Bianchi G, D’Ambrosio D, Albanesi C, Stoppacciaro A, Chieppa M, Allavena P, Ruco L, Girolomoni G, Sinigaglia F, Vecchi A, Mantovani A. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest. 2001; 107: 1173–1181.[Medline] [Order article via Infotrieve]
29. Schonbeck U, Libby P Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation. 2004; 109 (Suppl II): II18–II26.
30. Tanaka T, Soejima H, Hirai N, Sakamoto T, Yoshimura M, Kajiwara I, Miyao Y, Fujimoto K, Miyagi H, Irie A, Nishimura Y, Ogawa H. Comparison of frequency of interferon-gamma-positive CD4+ T cells before and after percutaneous coronary intervention and the effect of statin therapy in patients with stable angina pectoris. Am J Cardiol. 2004; 93: 1547–1549.[Medline] [Order article via Infotrieve]
31. Fehr T, Kahlert C, Fierz W, Joller-Jemelka HI, Riesen WF, Rickli H, Wuthrich RP, Ammann P. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis. 2004; 175: 83–90.[CrossRef][Medline] [Order article via Infotrieve]
32. Stuve O, Youssef S, Steinman L, Zamvil SS. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol. 2003; 16: 393–401.[CrossRef][Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				H. Loppnow, K. Werdan, and M. Buerke Invited review: Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms Innate Immunity, April 1, 2008; 14(2): 63 - 87. [Abstract] [PDF]

				X. P. Yang, S. Mattagajasingh, S. Su, G. Chen, Z. Cai, K. Fox-Talbot, K. Irani, and L. C. Becker Fractalkine Upregulates Intercellular Adhesion Molecule-1 in Endothelial Cells Through CX3CR1 and the Jak Stat5 Pathway Circ. Res., November 9, 2007; 101(10): 1001 - 1008. [Abstract] [Full Text] [PDF]

				A.O. Kraaijeveld, S.C.A. de Jager, W.J. de Jager, B.J. Prakken, S.R. McColl, I. Haspels, H. Putter, T.J.C. van Berkel, L. Nagelkerken, J.W. Jukema, et al. CC Chemokine Ligand-5 (CCL5/RANTES) and CC Chemokine Ligand-18 (CCL18/PARC) Are Specific Markers of Refractory Unstable Angina Pectoris and Are Transiently Raised During Severe Ischemic Symptoms Circulation, October 23, 2007; 116(17): 1931 - 1941. [Abstract] [Full Text] [PDF]

				V. Bjerkeli, J. K. Damas, B. Fevang, J. C. Holter, P. Aukrust, and S. S. Froland Increased expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in Wegener's granulomatosis possible role in vascular inflammation Rheumatology, September 1, 2007; 46(9): 1422 - 1427. [Abstract] [Full Text] [PDF]

				J. Barlic, Y. Zhang, and P. M. Murphy Atherogenic Lipids Induce Adhesion of Human Coronary Artery Smooth Muscle Cells to Macrophages by Up-regulating Chemokine CX3CL1 on Smooth Muscle Cells in a TNF{alpha}-NF{kappa}B-dependent Manner J. Biol. Chem., June 29, 2007; 282(26): 19167 - 19176. [Abstract] [Full Text] [PDF]

				M Brueckmann and M Borggrefe Therapeutic potential of fractalkine: a novel approach to metastatic colon cancer Gut, March 1, 2007; 56(3): 314 - 316. [Full Text] [PDF]

				A. Schafer, C. Schulz, D. Fraccarollo, P. Tas, M. Leutke, M. Eigenthaler, S. Seidl, P. Heider, G. Ertl, S. Massberg, et al. The CX3C Chemokine Fractalkine Induces Vascular Dysfunction by Generation of Superoxide Anions Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 55 - 62. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Data Supplement All Versions of this Article: 25/12/2567    most recent 01.ATV.0000190672.36490.7bv1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Damås, J. K. Articles by Quehenberger, O. Search for Related Content PubMed PubMed Citation Articles by Damås, J. K. Articles by Quehenberger, O.